Aug. 25 at 5:50 PM
🚀
$ADTX Bull Case with completed Merger + IPO
• Current cap: ~
$6M
• Pro-forma TTM revenue (w/
$EVFM merger): ~
$16.6M
• Merger adds Phexxi + synergies →
$30M+ revenue path
• Pearsanta IPO (H2 2025) = potential game-changer in cancer Dx 🚑
• Base case:
$100M valuation (≈15× upside)
• Bull case:
$300M+ (50×) 💥
At ~
$1/share, ADTX looks like pure asymmetric upside.
#Biotech #GrowthStock